<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953367</url>
  </required_header>
  <id_info>
    <org_study_id>12012.102</org_study_id>
    <nct_id>NCT01953367</nct_id>
  </id_info>
  <brief_title>Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects</brief_title>
  <official_title>Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pari Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pari Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the bioequivalence and compare the safety profiles following
      inhalation of Vantobra to TOBI nebulizer solution in healthy subjects.

      Bioequivalence will be investigated based on the pharmacokinetic plasma profiles of Vantobra
      nebulizer solution compared to TOBI nebulizer solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the bioequivalence (in terms of relative systemic bioavailability based on pharmacokinetic plasma profiles) of Vantobra 170 mg/1.7 mL nebulizer solution as compared to TOBI 300 mg/5 mL nebulizer solution in healthy subjects</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Plasma AUClast of tobramycin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the bioequivalence (in terms of relative systemic bioavailability based on pharmacokinetic plasma profiles) of Vantobra 170 mg/1.7 mL nebulizer solution as compared to TOBI 300 mg/5 mL nebulizer solution in healthy subjects</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Plasma Cmax of tobramycin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the bioequivalence (in terms of relative systemic bioavailability based on pharmacokinetic plasma profiles) of Vantobra 170 mg/1.7 mL nebulizer solution as compared to TOBI 300 mg/5 mL nebulizer solution in healthy subjects</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>tmax of tobramycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events during the trial period</measure>
    <time_frame>Adverse Events during the study period of max. 17 days</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Vantobra; Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOBI; Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TOBI, 300 mg tobramycin/5 mL nebulizer solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vantobra (tobramycin)</intervention_name>
    <description>Inhalation</description>
    <arm_group_label>Vantobra; Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOBI (tobramycin)</intervention_name>
    <description>Inhalation</description>
    <arm_group_label>TOBI; Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female healthy subjects of any ethnic origin

          -  Aged between 18 and 50 years of age

          -  Body weight of â‰¥50 kg and body mass index (BMI) between 18.5 and 29 kg/m2

          -  FEV1 &gt; 90% of predicted

          -  Able to demonstrate correct inhaler use

          -  Written informed consent

        Exclusion Criteria:

          -  History of clinically relevant allergies or idiosyncrasies to tobramycin or any other
             inactive ingredient(s) of the IMP

          -  Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic
             diathesis.

          -  Any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal,
             hematological, endocrinological, metabolic, neurological, psychiatric or other
             diseases at screening

          -  Surgery of the gastrointestinal or respiratory tract which might interfere with drug
             absorption

          -  History of malignancy within the past 5 years

          -  History of orthostatic hypotension, faintings or blackouts

          -  Acute or chronic viral, bacterial or fungal airway infections, including laryngeal
             infections, mouth and throat infections, and hoarseness;

          -  Other clinically relevant chronic or acute infectious illnesses

          -  Clinical chemical, hematological or any other laboratory parameters clinically
             relevant outside the normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolgang Timmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inamed GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inamed GmbH</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

